Science Pool

Date: 23-24 November, 2022

Venue: ENS Lyon, France

Attendees: Sebastien Coyne (Group Leader In Vitro Biology ID), Francesca Bernardini (VP In Vitro Biology & AMR Lead), Antoine Alam (VP Head of Virology), Lilia Boucinha (Team Leader, Global Bioinformatics), Christelle Dagoneau (SVP Business Development) Nadir Bessila (Business Development Executive) and Florian Marro (Research Associate, Mass Spectrometry & Phenomics)

Evotec will be sponsoring this year’s I4ID conference as well as showcasing its research on-site in Lyon.

Oral Presentation: Leveraging Continuous Manufacturing to Expand Global Access to Biotherapeutics - Presentation by Christelle Dagoneau

During this session, Christelle will present a unique platform concept that integrates the discovery, development, and manufacture of biologics in innovative and easily deployable production facilities called J.POD. She will particularly describe how the Just-Evotec Biologics cutting-edge AI/ML protein design technologies combined with industry-leading intensified continuous bioprocess can help de-risk and accelerate biotherapeutics development from lead generation through to BLA while offering cost-effective and truly flexible clinical and commercial supply solutions.

Oral Presentation: Alternative Approach to Discover Small Molecule Antibiotics - Presentation by Sebastien Coyne

Discovering new antibacterial drugs is urgently needed but represents many challenges. Alternative approaches to discover such new drugs are currently being explored and might offer a promising solution. We present one alternative approach that consists of screening for antibacterial drugs in in vivo mimetic medium. These culture conditions, defined to better reflect the conditions a bacterium would face at an infection site, allowed to discover active small molecules with new mode of action and/or representing novel chemical matter.

Poster Presentation by Florian Marro: Intracellular Staphylococcus aureus replicative dynamics monitoring under antibiotics challenges: highlighting persiste

If you wish to meet with us in Lyon, get in touch via the form below, we will be happy to arrange a meeting.

Learn more about the 6th I4ID congress

Date: 3 - 6 November, 2022

Attendee: Tobias Bohnenpoll (Research Scientist, Metabolic Diseases)

Our scientific program:

Poster: Unsupervised Characterization of the NURTuRE Cohort Reveals Gene Expression and Tissue Remodeling Dynamics Along a Synthetic CKD Progression Axis

Presented by Tobias Bohnenpoll, Ph.D., Research Scientist at Evotec on 5 November from 10:00am - 12:00pm EDT

Oral Abstract Session: A Multi-Omics Approach to IgA Nephropathy Characterization in the NURTuRE Cohort Enables Precision-Based Treatment Approaches

This live presentation will showcase work done within a strategic partnership between Evotec SE and Chinook Therapeutics. 

Presented by Eric Olson, Ph.D., Director, Bioinformatics and Computational Biology at Chinook Therapeutics on 4 November from 4:30 - 6:00pm EDT

Date: 17 - 18 November, 2022

Venue: Encore Boston Harbor, Boston, MA

Attendees: Todd Ireland (Senior Director Business Development) and Cenk Cetin (VP Business Development)

Evotec and Just-Evotec Biologics will be attending the Pharma Partnering Summit in Boston, MA.

If you wish to meet with us in Boston, get in touch via the form below, we will be happy to arrange a meeting.

Learn more about the Pharma Partnering US Summit

Date: 2 - 4 November, 2022

Venue: Congress Centre, Basel, Switzerland

Attendees: Christelle Dagoneau (SVP Business Development), Thierry Wurch (SVP Integrated Biologics Discovery), and Nigel Shipston (Senior Director Business Development)

Evotec and Just-Evotec Biologics will be attending and presenting its science at the Festival of Biologics in Basel.

Our scientific program:

Presentation: Paradigm Shift in Biologics Manufacturing: Leveraging Continuous Manufacturing and AI/ML Based Technologies From Discovery to Market Supply

During this session, Christelle Dagoneau will present a unique platform concept which integrates the discovery, development, and manufacture of biologics in innovative and easily deployable production facilities called J.POD. She will particularly describe how the Just-Evotec Biologics cutting-edge AI/ML protein design technologies combined with industry-leading intensified continuous bioprocess can help de-risk and accelerate biotherapeutics development from lead generation through to BLA while offering cost-effective and truly flexible clinical and commercial supply solutions.

Presented by Christelle Dagoneau, SVP Business Development at Just-Evotec Biologics on 2 November at 17:10 CET

Presentation: Evotec's Integrated Biologics Discovery and Development Platform to Strengthen Immunotherapy Research Programs

At Evotec, we discover, develop and manufacture novel medicines for hard-to-treat diseases through efficient partnerships with academia, biotechs and pharma. Our discovery efforts focus on data-driven precision medicine and early disease relevance to improve success rates in identifying best-in-class therapeutics.

To support immunotherapy research projects, we developed an integrated discovery platform ranging from target validation, antibody discovery and optimization, in vitro/in vivo pharmacology, PK, and toxicology to select the best clinical candidates. By applying both humanized mouse-derived hybridoma and phage display coupled to AI/ML-based optimization, antibodies are selected based on disease relevant, target related in vitro and in vivo models. Applications for the identification of immune-modulating molecules will be discussed.

Presented by Theirry Wurch, SVP Integrated Biologics Discovery on 3 November at 17:20 CET

Poster: Conversion of an Intensified Fed-Batch to an Integrated Continuous Bioprocess

Despite advances in upstream and downstream Integrated Continuous Bioprocessing (ICB) technologies, reducing manufacturing costs and process development costs continue to be a concern.

Conversion of a fed-batch (FB) or intensified fed-batch (IFB) process into a hybrid or end-to-end ICB process may be particularly challenging but manageable using key platform elements: high specific productivity cell lines, low-cost, concentrated perfusion media formulations, an optimized and scalable cell-retention device, and the impact to product quality remains as a potential issue stemming from higher culture cell densities, longer culture durations, and differences in product residence times.

This work involved the rapid conversion of an IFB mAb process to a hybrid ICB process using the Just-Evotec Biologics platform, resulting in several key project accomplishments:

• Mitigation of upstream IFB challenges: Filter fouling due to higher culture cell densities and durations was addressed by controlling cell density and implementing continuous harvest (CH).
• Significant productivity increase: 5-fold increase in product mass per working volume compared to original FB process at the 500L manufacturing scale.
• Short development time: < 6 months from project start to cGMP batch completion.
• Minimal risk from changes in product quality: most attributes (HMW and rCE) and process impurities (HCP, DNA, and Pro-A) were comparable (minor differences in glycan distribution).
• These results demonstrate that the rapid conversion of FB and IFB mAb processes to ICB can be met when implementing a robust ICB platform, thus supporting the biotherapeutic industry’s need to quickly adapt to changing clinical and business circumstances.

If you wish to meet with us in Basel, get in touch via the form below, we will be happy to arrange a meeting.

Learn more about the Festival of Biologics

Date: 4-7 October, 2022

Venue: Maternushaus, Cologne, Germany

Attendees: Priyanka Kohli (Research Scientist, Metabolic Diseases), Akanksha Dixit (Research Scientist, Metabolic Diseases), Kirsty Holden (Senior BD Executive – Attending Virtually)

Evotec will be sponsoring this year’s European Cilia conference as well as showcasing its research on site in Cologne. Come visit us in person at booth #4.

If you wish to meet with us in Cologne, get in touch via the form below, we will be happy to arrange a meeting.

Learn more about the Cilia Conference.

Date: 7 October 2022

Venue: Heidelberg, Germany

Attendees: Friedrich Reinhard (VP Academic Partnerships) and Laurie Sarrat (Business Development Manager)

Evotec will be attending at this year’s BioRN Annual conference  as well as showcasing its research on site in Heidelberg.

If you wish to meet with us in Heidelberg, get in touch via the form below, we will be happy to arrange a meeting.

Learn more about the BioRN Annual Conference

Date: 4 - 7 October, 2022

Venue: Crowne Plaza Dublin - Blanchardstown

Attendees: Francesca Bernardini (VP In Vitro Biology) and Stephanie Sandiford (Senior Scientist II, Anti-Infectives)

Stephanie Sandiford will be presenting a poster: Abstract Number EA56, Wednesday, 5 October 2022 17.00-18.30, Thursday, 6 October 2022 17.15-18.15

Rapid endpoint method for the quantification of Mycobacterium tuberculosis (Mtb) subjected to three different treatment regimens within the hollow fibre system (HFS)

If you wish to meet with us in Münster, get in touch via the form below, we will be happy to arrange a meeting.

Learn more about the 10th GSCN Conference & 20 years of Stem Cell Network NRW.

Date: 12-14 October, 2022

Venue: PACIFICO Yokohama, Japan

Attendees: Nick Johnson, Megumi Ruben and Adam Stoten

Evotec will be at BioJapan, Asia's largest partnering event, in Yokohama. Join our experts to learn more about Evotec's capabilities and solutions for drug discovery and development.

If you wish to meet with us at BioJapan, get in touch via the Partnering system or the form below, we will be happy to arrange a meeting.

Learn more about BioJapan

Date: 13 September, 2022

Venue: LifeHub Lyon, France

Attendees: Lilia Boucinha, Team Leader, Global Bioinformatics

Lilia will be a panelist on the session entitled "Sustainability and digitalization of R&D in the era of open data and open innovation"

If you wish to meet with us in Lyon, get in touch via the form below, we will be happy to arrange a meeting.

Learn more about the Constellab Connect 2022

Date: 2-5 October, 2022

Location: Phoenix, Arizona, USA

Attendees: Yalda Sedaghat (Project Lead, ASO Platform)

Evotec will be attending and showcasing its research on site in Phoenix at the 18th Annula Meeting of the Oligonucleotide Therapeuitcs Society .

The oligonucleotide therapeutics platform at Evotec: fully integrated RNA drug discovery

Yalda Sedaghat, Project Lead, ASO Platform at Evotec, will be presenting.

If you wish to meet with us in Phoenix, get in touch via the form below, we will be happy to arrange a meeting.

Learn more about the Annual Meeting of the Oligonucleotide Therapeutics Society